Pioneering Affordable Access to Targeted Cancer Therapies
On July 4, 2019, Everest Pharma proudly introduced OLANIB, the company’s first globally launched generic product, available in both Olaparib 50 mg capsules and 150 mg tablets. OLANIB is the high-quality, cost-effective generic version of the FDA-approved LYNPARZA®, developed to address a critical need in oncology treatment worldwide.
Olaparib is a PARP inhibitor used in the management of multiple hard-to-treat cancers, including Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and also Prostate Cancer.
With the launch of OLANIB, Everest Pharma starts its journey withits commitment to making breakthrough cancer treatments more accessible, particularly in regions where affordability remains a significant barrier to care.
“We are proud to launch OLANIB, our first-ever global generic, as a high-quality alternative to LYNPARZA®. This milestone reflects our mission to deliver life-saving therapies with uncompromised quality, efficacy, and safety,” said Mr. AnwarulHoq, CEO of Everest Pharma.
The introduction of OLANIB marks a significant step toward expanding access to targeted cancer therapies that were once out of reach for many patients. By ensuring quality at a lower cost, Everest Pharma supports both healthcare systems and patients in achieving better outcomes through sustainable oncology care.
About Everest Pharma
Everest Pharma is a leading global pharmaceutical company dedicated to the development, manufacturing, and distribution of high-quality, affordable generic medicines. With a focus on oncology, infectious diseases, and other critical therapeutic areas, Everest Pharma is committed to enhancing global health through innovation, integrity, and impact.
For more information on OLANIB and our oncology portfolio, please visit:
